Xeris Biopharma (NASDAQ:XERS) Insider Steven Pieper Sells 5,000 Shares

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider Steven Pieper sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $8.50, for a total value of $42,500.00. Following the completion of the sale, the insider owned 1,361,053 shares in the company, valued at approximately $11,568,950.50. This represents a 0.37% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Steven Pieper also recently made the following trade(s):

• On Tuesday, July 7th, Steven Pieper sold 27,600 shares of Xeris Biopharma stock. The stock was sold at an average price of $8.52, for a total transaction of $235,152.00.
• On Monday, July 6th, Steven Pieper sold 17,400 shares of Xeris Biopharma stock. The shares were sold at an average price of $8.50, for a total transaction of $147,900.00.

Xeris Biopharma Stock Performance

Shares of XERS stock traded up $0.10 during trading hours on Wednesday, hitting $8.49. The company’s stock had a trading volume of 1,728,807 shares, compared to its average volume of 1,882,676. The stock has a market cap of $1.47 billion, a PE ratio of -77.18 and a beta of 0.66. Xeris Biopharma Holdings, Inc. has a 12-month low of $5.25 and a 12-month high of $10.08. The company has a 50 day moving average of $7.77 and a 200 day moving average of $6.80. The company has a current ratio of 2.12, a quick ratio of 1.50 and a debt-to-equity ratio of 17.00.

Xeris Biopharma (NASDAQ:XERS) last issued its earnings results on Thursday, August 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.01 by ($0.19). Xeris Biopharma had a positive return on equity of 158.10% and a negative net margin of 5.12%.The business had revenue of $92.10 million for the quarter, compared to analysts’ expectations of $90.12 million. On average, sell-side analysts forecast that Xeris Biopharma Holdings, Inc. will post 0.07 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently commented on XERS. Wall Street Zen lowered Xeris Biopharma from a “strong-buy” rating to a “buy” rating in a report on Saturday. Weiss Ratings raised shares of Xeris Biopharma from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, July 23rd. Four research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $10.80.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Kestra Advisory Services LLC acquired a new stake in Xeris Biopharma in the 4th quarter worth about $25,000. KBC Group NV acquired a new position in shares of Xeris Biopharma during the first quarter valued at approximately $27,000. Allworth Financial LP purchased a new position in shares of Xeris Biopharma in the second quarter valued at approximately $34,000. State of Wyoming purchased a new position in shares of Xeris Biopharma in the second quarter valued at approximately $52,000. Finally, Caitong International Asset Management Co. Ltd lifted its position in shares of Xeris Biopharma by 9,276.3% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 7,501 shares of the company’s stock valued at $59,000 after acquiring an additional 7,421 shares in the last quarter. Institutional investors and hedge funds own 42.75% of the company’s stock.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.